Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.

ABSTRACT:

Objective

Binge-eating disorder (BED) is a prevalent psychiatric disorder associated with obesity. Few evidence-based treatments exist for BED, particularly pharmacological options. This study tested the efficacy of naltrexone/bupropion for BED.

Methods

A randomized, double-blind, placebo-controlled, 12-week trial tested naltrexone/bupropion for BED with and without obesity. Eighty-nine patients (70.8% women, 69.7% White, mean age 45.7 y, mean BMI 35.1 kg/m² , 77.5% with BMI ≥ 30 kg/m² ) were randomized to placebo (n = 46) or naltrexone/bupropion (n = 43), with randomization stratified by obesity status and gender; 92.1% completed post-treatment assessments.

Results

Mixed models of binge-eating frequency revealed significant reductions that did n

SUBMITTER: Grilo CM 

PROVIDER: S-EPMC10600891 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature